Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCH-STAR: TNT vs iTNT in High-risk LARC
NCT07551479Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- May 2026
- Primary completion
- Dec 2032
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of serplulimab in locally advanced rectal cancer (LARC) (2 arms), sponsored by Fudan University. Primary endpoint: Event-Free Survival at 3 years. Planned start May 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
locally advanced rectal cancer (LARC)
Beyond the preview
Go deeper on NCT07551479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551479.